3-(4-Fluorophenyl)-1-(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole | 1097861-83-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-Fluorophenyl)-1-(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole
• 英文别名: 4-[5-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1,3-dihydropyrazol-4-yl]pyridine
• CAS: 1097861-83-0
• 化学式: C₂₁H₁₈FN₃OS
• 分子量: 379.458
• InChiKey: CJXIYKXBGARHCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-Amino-3-(4-fluorophenyl)-1-(methylthiophenyl)-4-(4-pyridyl)pyrazole 、 、 [4-(甲硫基)苯基]肼 、 2-(4-吡啶基)-3-(4-氟苯基)-3-氧代丙腈 生成 3-(4-Fluorophenyl)-1-(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole
  参考文献：
  名称：

  Compounds

  摘要：

  本发明涉及式（I）的新型吡唑化合物及包含式（I）化合物和药学上可接受的稀释剂或载体的制药组合物。本发明还涉及通过式（I）化合物抑制细胞因子的方法，并通过给予该化合物治疗哺乳动物的细胞因子介导疾病。

  公开号：

  US06306883B1

文献信息

• Process for making substituted pyrazoles
  申请人：——

  公开号：US20030144302A1

  公开（公告）日：2003-07-31

  This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): 1 wherein R 3A , R 3B , R 3C , Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are as defined in the specification.

  这项发明通常涉及制备取代吡唑，取代吡唑的互变异构体，以及取代吡唑和互变异构体的盐的过程。这些取代吡唑在结构上对应于式（I）： 1 其中R 3A ，R 3B ，R 3C ，Y 1 ，Y 2 ，Y 3 ，Y 4 和Y 5 如规范中所定义。
• [EN] SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE LA KINASE p38
  申请人：SEARLE & CO

  公开号：WO2000031063A1

  公开（公告）日：2000-06-02

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R?1, R2, R3 and R4¿ are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。 特别感兴趣的化合物由公式（IA）定义，其中R?1，R2，R3和R4¿如规范中所述。
• Novel pyrazoles and their use as p38 kinase inhibitors
  申请人：——

  公开号：US20040082551A1

  公开（公告）日：2004-04-29

  This invention is directed generally to pyrazoles that, inter alia, inhibit p38 kinase, TNF, and/or cyclooxygenase-2 activity. Such pyrazoles include compounds generally corresponding in structure to the following formula: 1 wherein L 1 , L 2 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , R 1 , R 3A , R 3B , R 3C , R 4 , and R 5 are as defined in this specification. The pyrazoles further include tautomers of such compounds, as well as salts of such compounds and tautomers. This invention also is directed to compositions of such pyrazoles, intermediates for the syntheses of such pyrazoles, methods for making such pyrazoles, and methods for treating (including preventing) conditions (particularly pathological conditions) associated with p38 kinase, TNF, and/or cyclooxygenase-2 activity.

  本发明通常涉及对吡唑烷的研究，其中包括抑制p38激酶、TNF和/或环氧合酶-2活性的化合物。这些吡唑烷包括通常对应于以下结构式的化合物：1其中L1、L2、X1、X2、X3、X4、X5、X6、R1、R3A、R3B、R3C、R4和R5如本说明书所定义。这些吡唑烷还包括这些化合物的互变异构体，以及这些化合物和互变异构体的盐。本发明还涉及这些吡唑烷的组合物、合成这些吡唑烷的中间体、制备这些吡唑烷的方法，以及用于治疗（包括预防）与p38激酶、TNF和/或环氧合酶-2活性相关的病理条件的方法。
• 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors
  申请人：——

  公开号：US20040147579A1

  公开（公告）日：2004-07-29

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I 1 wherein R 1 , R 2 , Ar 1 and HetAr 2 are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式I1定义，其中R1、R2、Ar1和HetAr2如规范中所述。
• Pyrazole derivatives as p38 kinase inhibitors
  申请人：——

  公开号：US20030144529A1

  公开（公告）日：2003-07-31

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I 1 wherein Q, R 1 , R 2 , R 3 and R 4 are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式I1定义，其中Q、R1、R2、R3和R4如规范中所述。